Molecular Biomarkers Related to Oral Carcinoma: Clinical Trial Outcome Evaluation in a Literature Review von Santoro, Rossella, Laino, Luigi, Laino, Gregorio, Cicciù, Marco, De Stefano, Rosa, D’Amico, Cesare, Crimi, Salvatore, Bianchi, Alberto, Umberto, Romeo, Herford, Alan Scott, Fiorillo, Luca, Cervino, G., Troiano, Giuseppe

Volltext

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations von Thiel, William H., Thiel, Kristina W., Leslie, Kimberly K., Umesalma, Shaikamjad, Wang, Xinhao, Bi, Jianling, Devor, Eric J., Li, Yiyang, Li, Yujun, Yang, Shujie, Meng, Xiangbing, Quelle, Dawn E.

Volltext

Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials von Vora, Kruti B., Ricciuti, Biagio, Awad, Mark M.

Volltext

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer von Wang, Xinan, Ricciuti, Biagio, Tom Nguyen, Li, Xihao, Rabin, Michael S., Awad, Mark M., Lin, Xihong, Johnson, Bruce E., Christiani, David C.

Volltext

Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy von Bianconi, Vanessa, Sahebkar, Amirhossein, Kovanen, Petri, Bagaglia, Francesco, Ricciuti, Biagio, Calabrò, Paolo, Patti, Giuseppe, Pirro, Matteo

Volltext

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status von Ricciuti, Biagio, Arbour, Kathryn C., Lin, Jessica J., Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y., Li, Yvonne Y., Spurr, Liam F., Cherniack, Andrew D., Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V., Vaz, Victor R., Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J., Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M., Barbie, David, Altan, Mehmet, Heymach, John V., Skoulidis, Ferdinandos, Gainor, Justin F., Hellmann, Matthew D., Awad, Mark M.

Volltext

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis von Abu-Sbeih, Hamzah, Ali, Faisal S, Naqash, Abdul Rafeh, Owen, Dwight H, Patel, Sandipkumar, Otterson, Gregory A, Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K, Wang, Yinghong

Volltext

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer von Ricciuti, Biagio, Recondo, Gonzalo, Spurr, Liam F., Li, Yvonne Y., Lamberti, Giuseppe, Venkatraman, Deepti, Umeton, Renato, Cherniack, Andrew D., Nishino, Mizuki, Sholl, Lynette M., Shapiro, Geoffrey, Awad, Mark M., Cheng, Michael L.

Volltext

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer von Wang, Xinan, Ricciuti, Biagio, Alessi, Joao, Nguyen, Tom, Awad, Mark M., Lin, Xihong, Johnson, Bruce E., Christiani, David C.

Volltext

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligan... von Cortellini, Alessio, Bersanelli, Melissa, Santini, Daniele, Buti, Sebastiano, Tiseo, Marcello, Cannita, Katia, Perrone, Fabiana, Giusti, Raffaele, De Tursi, Michele, Zoratto, Federica, Marconcini, Riccardo, Russano, Marco, Zeppola, Tea, Anesi, Cecilia, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Tudini, Marianna, Silva, Rosa Rita, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Migliorino, Maria Rita, Mallardo, Domenico, Vanella, Vito, Mosillo, Claudia, Bracarda, Sergio, Rinaldi, Silvia, Berardi, Rossana, Natoli, Clara, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.

Volltext

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable von Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario Alberto, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria Concetta, Ascierto, Paolo Antonio, Ficorella, Corrado, Natoli, Clara

Volltext

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort von Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, Walker, Paul R.

Volltext

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC von Keegan, Alissa, Ricciuti, Biagio, Garden, Padric, Cohen, Limor, Nishihara, Reiko, Adeni, Anika, Paweletz, Cloud, Supplee, Julianna, Jänne, Pasi A, Severgnini, Mariano, Awad, Mark M, Walt, David R

Volltext

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) von Ricciuti, Biagio, Jones, Greg, Severgnini, Mariano, Alessi, Joao V, Recondo, Gonzalo, Lawrence, Marissa, Forshew, Tim, Lydon, Christine, Nishino, Mizuki, Cheng, Michael, Awad, Mark

Volltext

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients von Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, Buti, Sebastiano

Volltext

Association between immune-related adverse event timing and treatment outcomes von Hsiehchen, David, Naqash, Abdul Rafeh, Espinoza, Magdalena, Von Itzstein, Mitchell S., Cortellini, Alessio, Ricciuti, Biagio, Owen, Dwight H., Laharwal, Mehak, Toi, Yukihiro, Burke, Michael, Xie, Yang, Gerber, David E.

Volltext

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience von Ricciuti, Biagio, Baglivo, Sara, De Giglio, Andrea, Chiari, Rita

Volltext

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers von Cheong, Taek-Chin, Jang, Ahram, Wang, Qi, Leonardi, Giulia C., Ricciuti, Biagio, Alessi, Joao V., Di Federico, Alessandro, Awad, Mark M., Lehtinen, Maria K., Harris, Marian H., Chiarle, Roberto

Volltext

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence von Ricciuti, Biagio, Brambilla, Marta, Metro, Giulio, Baglivo, Sara, Matocci, Roberta, Pirro, Matteo, Chiari, Rita

Volltext

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks von De Giglio, Andrea, Ricciuti, Biagio, Metro, Giulio

Volltext